Table 2 |
|||
|
Predictive performance (and 95% confidence interval) of the DLDA30 predictor in patients treated with preoperative chemotherapy |
|||
| Breast tumors of any phenotype |
HER-2-positive breast tumors |
||
|
|
|||
| Performance metrics |
Validation cohort T/FACa n = 51 |
Present study cohort Trastuzumab + T/FEC n = 45 |
Subset of validation cohort T/FACa n = 30 |
|
|
|||
| Area under the curve |
0.877 (0.066) |
0.565 (0.089) |
0.81 (0.092) |
| Overall accuracy |
0.76 (0.62–0.87) |
0.51 (0.36–0.66) |
0.67 (0.47–0.83) |
| Sensitivity |
0.92 (0.64–1.00) |
0.52 (0.33–0.71) |
0.90 (0.56–1.00) |
| Specificity |
0.71 (0.54–0.85) |
0.50 (0.25–0.75) |
0.55 (0.32–0.77) |
| Positive predictive value |
0.52 (0.31–0.73) |
0.65 (0.43–0.84) |
0.50 (0.26–0.74) |
| Negative predictive value |
0.96 (0.82–1.00) |
0.36 (0.17–0.59) |
0.92 (0.62–1.00) |
|
|
|||
|
aHess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, et al. [17]. T/FAC, paclitaxel followed by 5-fluorouracil, doxorubicin, and cyclophosphamide; T/FEC, paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide. |
|||
|
Esteva et al. Breast Cancer Research 2007 9:R87 doi:10.1186/bcr1836 |
|||
